IgG-guided diet outperforms sham diet in clinical trial
Michigan Medicine and Cleveland Clinic researchers have found that patients with irritable bowel syndrome were more likely to ...
Johnson & Johnson reports progress on nipocalimab
HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...
Medscape2d
Intravenous Immunoglobulin IgG Response Associated with Poor Outcome in Guillain-Barré Syndrome
Total IgG levels were determined in serum samples pretreatment and again 2 weeks after treatment. Some patients also had IgG levels measured at 4 weeks (91 patients), 3 months (86 patients), and 6 ...
The American Journal of Managed Care2d
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...